The overarching aim of the Epidemic diseases Research Group Oxford (ERGO) is to reduce the health and socioeconomic impact of emerging infections.  We conduct and enable clinical research on emerging and epidemic infections, and some of our work can be found below;




ISARIC's purpose is to prevent illness and deaths from infectious disease outbreaks. ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.

Find out more on ISARIC's website at



The African coaLition for Epidemic Research, Response and Training (ALERRT) is a multi-disciplinary consortium building a patient-centered clinical research network to respond to epidemics across sub-Saharan Africa.

ALERRT aims to reduce the public health and socio-economic impact of disease outbreaks in sub-Saharan Africa by building a sustainable clinical and laboratory research preparedness and response network.

Find our more at

NIHR Health Protection Research Unit in Emerging and Zoonotic Infections

The overarching aim of the HPRU is to support and strengthen PHE in its role of protecting England from emerging and zoonotic infections. By bringing together internationally leading researchers at the University of Liverpool (UoL), University of Oxford, Liverpool School of Tropical Medicine (LSTM) and PHE, they exploit the synergy, world-class facilities, and breadth and depth in relevant research between these institutions.

More information at

Understanding the dynamics of policy development and healthcare worker behaviour in the UK during the Covid-19 public health emergency

Professor Sally Sheard (University of Liverpool) and Dr Nina Gobat (University of Oxford) lead this NIHR-funded project. It aims to analyse the UK pandemic response by collecting real-time responses from senior policymakers and stakeholders (PHE, DHSC, NHS) and the frontline experiences of healthcare workers, and by studying media and document sources. Their findings will inform senior policymakers.

Find out more at

RECOVER - Rapid European COVID-19 Emergency Response research

RECOVER is one of the 18 projects that the European Union has founded in response to the COVID-19 pandemic. It aims to obtain crucial unknown information about the disease through clinical research to help the EU fight the virus and save patients’ lives. 

The research from RECOVER will help improve the EU’s response to future epidemics and pandemics. 

Find out more at

RECOVERY Trial: Randomised Evaluation of COVID-19 Therapy

 Led by ERGO's Peter Horby,  this national clinical trial aims to identify treatments that may be beneficial for adults hospitalised with confirmed COVID-19. The trial is being conducted in over 130 NHS hospitals across the UK.  Adult patients who have been admitted to hospital with COVID-19 are being invited to take part, and more information can be found at   

UK-PHRST (UK Public Health Rapid Support Team)

The UK-PHRST, funded by UK aid from the Department of Health and Social Care, supports low- and middle-income countries in investigating and responding to disease outbreaks and conducts resesarch to improve our response to future epidemics. 

Find out more by visiting and

VEEPED - Vaccine Efficacy Evaluation for Priority Emerging Diseases

The VEEPED collaboration examines the feasibility of vaccine trial designs and optimal trial approaches using epidemiological analysis, transmission dynamic modelling and public health assessment, including engagement with stakeholders and collaboration with other vaccine research groups, including social scientists, field researchers and product developers.